Ethosuximide

CLINICAL USE

Epilepsy

DOSE IN NORMAL RENAL FUNCTION

500 mg – 2 g daily in divided doses

PHARMACOKINETICS

Molecular weight :141.2

%Protein binding :01

%Excreted unchanged in urine : 12–20

Volume of distribution (L/kg) :0.6–0.9

half-life – normal/ESRD (hrs) :40–60/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Dialysed. Dose as in normal renal function

HD :Dialysed. Dose as in normal renal function

HDF/high flux :Dialysed. Dose as in normal renal function

CAV/VVHD :Dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antibacterials: concentration increased by isoniazid

Antidepressants: lower convulsive threshold

Anti-epileptics: concentration possibly reduced by carbamazepine, phenytoin and primidone; concentration of phenytoin possibly increased; concentration increased by valproate

Antimalarials: possibly increased risk of convulsions with chloroquine and hydroxychloroquine; anticonvulsant effect antagonised by mefloquine

Antipsychotics: lower convulsive threshold

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home